Navigation Links
Neuralstem updates clinical trial progress
Date:5/24/2010

ROCKVILLE, Maryland, May 24, 2010 Neuralstem, Inc. (NYSE Amex: CUR) updated the progress of its ongoing Phase I human clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) at Emory University in Atlanta, Georgia. The company announced that, after reviewing the safety data from the first cohort of three patients, the Safety Monitoring Board has approved moving to the next cohort and transplantation of the fourth patient. The first cohort of patients received five injections of the Company's spinal cord stem cells on one side of the spinal cord. The second cohort of three patients will receive ten injections, five on each side of the cord.

About The Trial

The FDA-approved Phase I trial to evaluate the safety of Neuralstem's spinal cord stem cells in the treatment of ALS has been underway since January, 2010. The trial will ultimately consist of up to 18 ALS patients, who will be examined at regular intervals post-surgery, with final review of the data to come six months after the last patient is treated.


'/>"/>

Contact: Deanne Eagle
deanneeagle@gmail.com
917-837-5866
Neuralstem, Inc.
Source:Eurekalert

Page: 1

Related medicine news :

1. Neuralstem Receives Approval To Commence First ALS Stem Cell Trial at Emory ALS Center
2. Sutter Health Surgical Team Sends Updates From Haiti
3. CCH Updates Briefings on Tax Provisions of Estate Tax, Tax Extender, Health Care Reform Bills
4. Sunquest Announces Major Software Updates and Enhancements
5. Global Medical Products (GMDP) Selects Mina Mar Group as Its Corporate Advisor And Updates
6. American Traveler Offers New Healthcare Jobs Hourly, Updates Via Job RSS & Twitter
7. Clone Systems, Inc. Updates PCI Solutions for Level 1 & 2 Merchants
8. FDA Updates Import Alert 71-04 for Salmonella Contaminated Animal Feeds: Many Non-U.S. Firms Affected According to FDAImports.com, LLC
9. New "howsthepatient" iPhone App Provides a Simple, Seamless Way to Send Health Updates to Friends and Family
10. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
11. FDA Issues Guidance to Help Streamline Medical Device Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Via Oncology, the leading provider of oncology ... public-facing tool for analyzing the costs of various drug regimens in cancer care. ... patients, providers, insurers and pharmaceutical companies about the estimated costs of treatment options. ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... announces today that the University of Pittsburgh Medical Center (UPMC) will acquire QuikClot® ... Western Pennsylvania. , The program, developed in association with efforts by the American ...
(Date:3/28/2017)... ... ... Usually, the impending arrival of warmer weather means the gleeful banishment of ... chin, this means more anxiety than elation. The cosmetic dermatology experts at Cosmetic Laser ... chin is undesirable,” Dr. Goldman said, “but it seems doubly so when the fat ...
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, ... to ensuring high-quality results and maintaining GMP and USP compliance. In a new ... accordance with GMP requirements " these requirements are explained. The challenge is ...
(Date:3/28/2017)... ... 2017 , ... Qualidigm , the mission-driven national healthcare ... new, more expansive office space in order to accommodate its growing number of ... building in Wethersfield, Conn. located at 936 Silas Deane Highway and immediately began ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Market leading ... announced a partnership with premium news content provider ... companies to extract key insights from Dow Jones ... technology. The Linguamatics I2E platform is ... global pharmaceutical companies. The Linguamatics-Dow Jones partnership helps ...
(Date:3/28/2017)... , March 28, 2017  CASI Pharmaceuticals, ... innovative therapeutics addressing cancer and other unmet medical ... American Association for Cancer Research annual meeting.  The ... is entitled "Evaluation of ENMD-2076 in Combination ... the second poster to be presented on April ...
(Date:3/28/2017)... , March 28, 2017 Elysium ... with Cambridge academic ...   The Milner Therapeutics Institute today announces Elysium ... Health has committed significant investment for collaborative projects with academic ... four years. This is the first major research investment outside ...
Breaking Medicine Technology: